SCHEMBL2138689

SCHEMBL2138689

Cc1ccc(S(=O)(=O)n2cc(C=O)c3c(F)cccc32)cc1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.66
UBE2N P61088 1/20 0.66
HTR6 P50406 14/20 0.47
HTR2A P28223 3/20 0.47
HTR2C P28335 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.45
HTR1D P28221 1/20 0.43
HTR1B P28222 1/20 0.43
DRD3 P35462 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
POLB P06746 1/20 0.42
ALDH3A1 P30838 1/20 0.42
HTT P42858 1/20 0.42
NOD1 Q9Y239 1/20 0.42
ALOX5 P09917 1/20 0.38
ALK Q9UM73 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28487946 0.85 KDM4E (0.66) KDM4EUBE2NHTR6HTR2AHTR2C
SCHEMBL28510790 0.85 KDM4E (0.66) KDM4EUBE2NHTR6HTR2AHTR2C
SCHEMBL28493425 0.85 KDM4E (0.66) KDM4EUBE2NHTR6HTR2AHTR2C
SCHEMBL2945658 0.83 CA2 (0.50) KDM4EUBE2NHTR6HTR2AHTR2C
SCHEMBL2945655 0.83 CA2 (0.50) KDM4EUBE2NHTR6HTR2AHTR2C
SCHEMBL6625206 0.82 KDM4E (0.65) KDM4EUBE2NHTR6HTR2AHTR2C
SCHEMBL13257973 0.82 HTR6 (0.52) KDM4EUBE2NHTR6HTR2AHTR2C
SCHEMBL17422026 0.81 HTR6 (0.69) KDM4EUBE2NHTR6HTR2AHTR2C
SCHEMBL2137464 0.81 KDM4E (0.64) KDM4EUBE2NHTR6HTR2AHTR2C
SCHEMBL2137648 0.80 KDM4E (0.46) KDM4EUBE2NHTR6HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3632899-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RaQualia Pharma Inc. (JP) 2020-04-08 EP disclosed
EP-2435407-B1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC (JP) 2019-12-25 EP disclosed
US-9522140-B2 Aryl substituted carboxamide derivatives as calcium or sodium channel blockers RAQUALIA PHARMA INC. (JP) 2016-12-20 US disclosed
US-20150322052-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC (JP) 2015-11-12 US disclosed
US-9101616-B2 Aryl substituted carboxamide derivatives as calcium or sodium channel blockers RAQUALIA PHARMA INC. (JP) 2015-08-11 US disclosed
US-20120101105-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 US disclosed
WO-2010137351-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC. (JP) 2010-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101105-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS CACNA1I, CACNA1G, CACNA1H KDM4E 837/4885UBE2N 4408/4885HTR6 1715/4885
US-20150322052-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS CACNA1I, CACNA1G, CACNA1H KDM4E 830/4885UBE2N 4410/4885HTR6 1699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.